### Key facts
| Item | Detail |
|---|---|
| Legal name | Wacker Chemie AG |
| Former names | Dr. Alexander Wacker Gesellschaft für elektrochemische Industrie (founding entity, 1914); Wacker-Chemie GmbH (GmbH form used for most of the 20th century; converted to AG in 2005 ahead of the IPO) |
| Founded | 1914, by Dr. Alexander Wacker. The Burghausen plant began operating during World War I. |
| Incorporation jurisdiction | Federal Republic of Germany (Aktiengesellschaft; two-tier board under the German Stock Corporation Act) |
| Headquarters | WACKER House, Werksviertel district, Munich. Address on 2026 press releases: Gisela-Stein-Straße 1, 81671 Munich. The previous HQ address, Hanns-Seidel-Platz 4, 81737 Munich, still appears in some third-party directories. |
| Stock exchange / tickers | Frankfurt Stock Exchange (Xetra): WCH. Bloomberg: WCH GR. Reuters: WCHG.DE. US OTC (unsponsored): WKCMF |
| ISIN / WKN | DE000WCH8881 / WCH888 |
| CUSIP | None. There is no SEC registration and no sponsored ADR. |
| IPO | 10 April 2006 |
| Share capital | EUR 260,763,000, split into 52,152,600 bearer shares. Of these, 49,677,983 are outstanding (excluding treasury) and 2,474,617 are treasury shares (about 4.7%). |
| Fiscal year end | 31 December |
| Employees (31 Dec) | 2025: 16,467; 2024: 16,637; 2023: 16,378; 2022: 15,725 |
| German workforce (2025) | 10,749 employees in Germany; 5,718 abroad |
| Auditor | PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft. PwC gave an unqualified opinion on the FY2025 consolidated statements (AR2025, Executive Board declaration). The previous long-standing auditor was KPMG. |
| Market capitalisation | EUR 3,445.2M at 31 Dec 2025 (EUR 69.35 per share; AR2025). About EUR 4.34bn at EUR 87.45 on 13 Sep 2026 (derived: 49.68M outstanding shares × price). Some data vendors quote about EUR 4.5–4.7bn using the total share count including treasury shares. |
| Credit rating | None published. Wacker states it relies on bank credit lines and promissory notes (Schuldschein) and does not issue rated instruments (AR2025). |
| Website | www.wacker.com |
| Business divisions | Silicones, Polymers, Biosolutions, Polysilicon |
| FY2025 headline figures | Sales EUR 5,485.3M; reported EBITDA EUR 426.7M; EBITDA before special items about EUR 529M; net result EUR -804.9M; no dividend |
Wacker Chemie is a Munich-headquartered, family-controlled, integrated chemicals group. Its two root raw materials are metallurgical silicon and ethylene.
From these it builds four businesses:
**Silicones:** This is about half of group sales and is one of the world's broadest silicone portfolios.
**Polymers:** This division is a global leader in vinyl acetate-ethylene (VAE) dispersions and dispersible polymer powders, sold mainly into construction.
**Polysilicon:** This division supplies hyperpure semiconductor- and solar-grade silicon from Burghausen, Nünchritz and Charleston (USA).
**Biosolutions:** This is a smaller biotech and contract-manufacturing (CDMO) unit spanning fermentation products, cyclodextrins, proteins and mRNA.
The group's strengths are process integration in a closed chlorine-silicon loop, deep application know-how and a German-centred asset base.
That same German base is now its principal weakness. High energy costs, Chinese overcapacity in silicones and polysilicon, and weak construction demand drove a EUR -805M net loss in FY2025.
Management's response is the PACE programme, targeting more than EUR 300M of annual cost savings by 2027. It is paired with a pivot toward specialties, semiconductor-grade polysilicon and biotech.
---
### What the company does
Wacker converts two feedstock chains into intermediate and specialty materials sold business-to-business.
1. **The silicon chain.** Metallurgical silicon is converted into chlorosilanes, then into siloxanes and silicones, pyrogenic (fumed) silica, and hyperpure polysilicon.
2. **The ethylene chain.** Ethylene and acetic acid are converted into vinyl acetate monomer (VAM), then into VAE dispersions, dispersible polymer powders, and solid resins.
The defining feature is integration. By-products of one step are feedstocks for another, especially in the silicon/chlorine and hydrogen-chloride loops at Burghausen and Nünchritz. This supports cost position and resource efficiency, but it also creates high fixed costs and utilisation sensitivity. Management repeatedly cites low plant utilisation as a FY2025 earnings drag (FY2025 press release).
### The company's own description (paraphrased from AR2025 and releases)
Wacker describes itself as a globally active chemical company with four business divisions. It develops and manufactures products, intermediates and technologies for virtually all key industries.
It positions its chemical divisions on specialties, its polysilicon division on the semiconductor market, and Biosolutions on biotech solutions. This three-part strategic focus was articulated by CEO Christian Hartel at the FY2025 annual press conference (11 Mar 2026).
### Independent characterisation
Wacker is best understood as a cyclical, energy-intensive, process-integrated materials company carrying a growing specialty overlay. Commodity exposure remains material in three places:
- standard silicones (siloxanes and fluids);
- solar-grade polysilicon;
- part of the VAE and powders business.
These are precisely where Chinese capacity additions have destroyed pricing.
The specialty overlay is real but not yet dominant. Examples include:
- liquid silicone rubber (LSR);
- medical-grade and electronics silicones;
- silane-terminated polymers;
- semiconductor-grade polysilicon;
- biologics CDMO.
The FY2022 peak (EBITDA EUR 2.08bn, 25.4% margin) and the FY2025 trough (reported EBITDA EUR 427M, 7.8% margin) show an earnings amplitude typical of commodity chemicals rather than specialty peers.
### Revenue model
| Revenue type | Approximate share | Description |
|---|---|---|
| Product sales (chemicals and materials) | About 97% (derived: everything except Biosolutions' service component) | Spot and contract sales of silicones, polymers and polysilicon. Polysilicon historically relied on multi-year supply agreements with prepayments, especially for solar. |
| Contract manufacturing services (CDMO) | Part of Biosolutions (division sales EUR 360.4M in FY2025, 6.6% of group); service share not separately disclosed | Fee-for-service development and GMP manufacture of biologics, mRNA, plasmid DNA and live biotherapeutics via Wacker Biotech (Jena, Halle, Amsterdam, León, San Diego) |
| Licensing / subscription | Not material; not separately disclosed | Some process-technology know-how, not reported as a revenue line |
| "Other" segment | EUR 142.2M in FY2025 (2.6%) | Infrastructure and site services, corporate items |
### Value-chain position
**Upstream:** Wacker produces part of its own silicon metal at Holla, Norway. It buys the remainder, plus ethylene, methanol, acetic acid and energy (electricity and gas), largely in Germany.
**Midstream (core):** Chlorosilanes, siloxanes, VAM and polysilicon.
**Downstream:** Formulated specialty products sold to OEMs and formulators. Wacker does not generally sell to end consumers.
### Customer types and end-markets
| End-market | Primary divisions | Key applications |
|---|---|---|
| Construction | Polymers, Silicones | Tile adhesives, self-levelling compounds, external insulation (ETICS), sealants, masonry protection, paints |
| Automotive and transportation | Silicones | Gaskets, cables, EV battery thermal management, LSR parts |
| Electrical and electronics | Silicones, Polysilicon | Encapsulants, potting compounds, high-voltage insulators, semiconductor wafers (via the Siltronic and other wafer customers) |
| Semiconductors | Polysilicon | Hyperpure polysilicon for Czochralski (CZ) and float-zone (FZ) crystal pulling |
| Solar / photovoltaics | Polysilicon | Solar-grade polysilicon |
| Personal care and consumer goods | Silicones, Biosolutions | Emollients, hair-care silicones, cyclodextrins |
| Textiles, paper, coatings | Silicones, Polymers | Release coatings, softeners, binders |
| Medical and healthcare | Silicones, Biosolutions | Medical-grade silicones, pharmaceutical proteins, mRNA, vaccines |
| Food and agriculture | Biosolutions, Polymers | Cysteine, gum-base resins (polyvinyl acetate), nutraceutical actives |